Clinical Trial

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP

Study acronym: INVGOR
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 16, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to potentially help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-10.
Status change: Recruiting → Active, Not Recruiting 2026-04-13
Trial Details
NCT Number NCT07027111
Lead Sponsor Nuvig Therapeutics, Inc.
Conditions Chronic Inflammatory Demyelinating Polyneuropathy
Enrollment 60 participants
Start Date 2025-04-25
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-16